Literature DB >> 17237447

Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus.

Vasileios C Kyttaris1, Ying Wang, Yuang-Taung Juang, Arthur Weinstein, George C Tsokos.   

Abstract

T cells from patients with systemic lupus erythematosus (SLE) are characterized by heightened TCR-initiated free intracytoplasmic calcium responses. We demonstrate that activated T cells from SLE patients, but not from rheumatoid arthritis patients, displayed higher levels of the calcineurin-dependent transcription factor NF-ATc2 in the nucleus compared with control T cells. DNA NF-AT-binding activity was also increased, as was the amount of NF-ATc2 bound to the promoters of CD154 (CD40L) and IL-2 genes. Nevertheless, although high NF-ATc2 levels translated into higher CD154 transcription in SLE, IL-2 transcription was decreased. The absence of important transcriptional activators (AP-1, NF-kappaBeta) and the presence of transcriptional repressors (cAMP response element modulator) on the IL-2 promoter explain this dichotomous effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237447     DOI: 10.4049/jimmunol.178.3.1960

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis.

Authors:  Jay Mehta; Anna Genin; Michael Brunner; Lisabeth V Scalzi; Nilamadhab Mishra; Timothy Beukelman; Randy Q Cron
Journal:  Arthritis Rheum       Date:  2010-08

3.  Estrogen upregulates cyclic AMP response element modulator α expression and downregulates interleukin-2 production by human T lymphocytes.

Authors:  Vaishali R Moulton; Dana R Holcomb; Melissa C Zajdel; George C Tsokos
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

4.  Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells.

Authors:  Gregory L Szeto; Joel L Pomerantz; David R M Graham; Janice E Clements
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

5.  Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.

Authors:  Heather M Gibson; Carrie J Hedgcock; Barbara M Aufiero; Adam J Wilson; Mikehl S Hafner; George C Tsokos; Henry K Wong
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

Review 6.  Pathogenesis of Skin Injury of Systemic Lupus Erythematosus.

Authors:  Guo-Min Deng
Journal:  Curr Rheumatol Rep       Date:  2018-02-21       Impact factor: 4.592

7.  Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus.

Authors:  Stella A Nicolaou; Lisa Neumeier; Koichi Takimoto; Susan Molleran Lee; Heather J Duncan; Shashi K Kant; Anne Barbara Mongey; Alexandra H Filipovich; Laura Conforti
Journal:  Cell Calcium       Date:  2009-12-02       Impact factor: 6.817

Review 8.  Small molecules in the treatment of systemic lupus erythematosus.

Authors:  Anastasia Markopoulou; Vasileios C Kyttaris
Journal:  Clin Immunol       Date:  2012-10-02       Impact factor: 3.969

9.  Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L expression and memory phenotype.

Authors:  Ameet A Chimote; Peter Hajdu; Leah C Kottyan; John B Harley; Yeoheung Yun; Laura Conforti
Journal:  J Autoimmun       Date:  2016-03-16       Impact factor: 7.094

10.  Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes.

Authors:  Stella A Nicolaou; Lisa Neumeier; Ashleigh Steckly; Vladimir Kucher; Koichi Takimoto; Laura Conforti
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.